AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7580831 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted formol-inactivated interferon alpha-2a (IFN alpha)
Number of subjects: 12
Study 7580831 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant alone (placebo)
Number of subjects: 12
Study 2255521 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate-buffered lidocaine-epinephrine-hyaluronidase
Number of subjects: 21
Study 2255521 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered lidocaine-epinephrine-hyaluronidase
Number of subjects: 21
Study 7438679 — intervention group
Group type: EXPERIMENTAL
Intervention: Metolazone
Number of subjects: 18
Study 7438679 — intervention group
Group type: COMPARATOR
Intervention: Bendroflumethiazide
Number of subjects: 18
Study 30936377 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologists' estimates of expected survival time (EST)
Number of subjects: 152
Study 30936377 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst-case scenario derived from EST
Number of subjects: 152
Study 30936377 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical scenario derived from EST
Number of subjects: 152
Study 30936377 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-case scenario derived from EST
Number of subjects: 152
Study 29752604 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone submucosally
Number of subjects: 45
Study 29752604 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone submucosally
Number of subjects: 45
Study 29752604 — intervention group
Group type: COMPARATOR
Intervention: Normal saline submucosally (control group)
Number of subjects: 45
Study 27430336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance and endurance training (3x/week)
Number of subjects: 250
Study 27430336 — intervention group
Group type: COMPARATOR
Intervention: Weekly care management phone calls (CMPCs)
Number of subjects: 250
Study 24681761 — intervention group
Group type: EXPERIMENTAL
Intervention: POWeR plus coaching
Number of subjects: 786
Study 24681761 — intervention group
Group type: EXPERIMENTAL
Intervention: POWeR only
Number of subjects: 786
Study 24681761 — intervention group
Group type: COMPARATOR
Intervention: POWeR plus coaching and POWeR only
Number of subjects: 786
Study 22561875 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg/d
Number of subjects: 0
Study 22561875 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/d
Number of subjects: 0
Study 20189333 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet received at home before the first visit (G1)
Number of subjects: 269
Study 20189333 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet received during the first visit (G2)
Number of subjects: 269
Study 20189333 — intervention group
Group type: COMPARATOR
Intervention: No leaflet received (G3)
Number of subjects: 269
Study 20189333 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall absenteeism rate
Number of subjects: 269
Study 18997198 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 or 100 mg per day)
Number of subjects: 2539
Study 18997198 — intervention group
Group type: COMPARATOR
Intervention: Nonaspirin group
Number of subjects: 2539
Study 18997198 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 2539
Study 16227633 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil/leucovorin (5‐FU/LV)
Number of subjects: 499
Study 16227633 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU/LV and interferon Alfa‐2a (IFNA‐2a)
Number of subjects: 499
Study 16227633 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU/LV and pelvic chemoradiotherapy
Number of subjects: 499
Study 16227633 — intervention group
Group type: COMPARATOR
Intervention: Pelvic chemoradiotherapy alone
Number of subjects: 499
Study 12825781 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulation group (self-testing techniques)
Number of subjects: 0
Study 12825781 — intervention group
Group type: COMPARATOR
Intervention: Strategy-control group (standard strategies only)
Number of subjects: 0
Study 12825781 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 10227571 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsers (n = 26)
Number of subjects: 51
Study 8688340 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous tamoxifen therapy beyond 5 years
Number of subjects: 342
Study 8688340 — intervention group
Group type: COMPARATOR
Intervention: Stopping tamoxifen at 5 years
Number of subjects: 342
Study 1884668 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg)
Number of subjects: 76
Study 1884668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 6342456 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures (study group)
Number of subjects: 46
Study 6342456 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 31932939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemovac drain
Number of subjects: 114
Study 31932939 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing technique
Number of subjects: 114
Study 31932939 — intervention group
Group type: COMPARATOR
Intervention: Non-drain group (control)
Number of subjects: 114
Study 30945169 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance expectations regarding the (ir) relevant stimuli formed in Experiment 1
Number of subjects: 0
Study 30945169 — intervention group
Group type: EXPERIMENTAL
Intervention: No concrete advance expectations formed in Experiment 2
Number of subjects: 0
Study 28234590 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received radiographs only when clinically indicated)
Number of subjects: 39
Study 28234590 — intervention group
Group type: COMPARATOR
Intervention: Control group (received screening radiographs immediately after fixation and at 2 weeks)
Number of subjects: 39
Study 28234590 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 39
Study 28234590 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 25787998 — intervention group
Group type: EXPERIMENTAL
Intervention: United Kingdom dietary guidelines
Number of subjects: 165
Study 25787998 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional British diet)
Number of subjects: 165
Study 23512339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 20944071 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation patterns in cells relevant to the pathogenesis of myeloma plasma cells
Number of subjects: 0
Study 20944071 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation patterns in myeloma stage
Number of subjects: 0
Study 20944071 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation patterns at the transition from myeloma to plasma cell leukemia
Number of subjects: 0
Study 20944071 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation variability within presentation myeloma samples
Number of subjects: 0
Study 20944071 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation subgroups defined by translocations and hyperdiploidy
Number of subjects: 0
Study 20944071 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperdiploid samples identified by unsupervised clustering
Number of subjects: 0
Study 20944071 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation changes during disease progression
Number of subjects: 0
Study 19170853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle changes (detailed advice on reducing body weight, improving diet quality, and increasing physical activity)
Number of subjects: 209
Study 19170853 — intervention group
Group type: COMPARATOR
Intervention: General information about healthy food choices and guidance on increasing physical activity (control group)
Number of subjects: 209
Study 17558069 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine 45 g/day for 5 days in addition to standard care (group A)
Number of subjects: 120
Study 17558069 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (group B)
Number of subjects: 120
Study 15284957 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 88
Study 15284957 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 88
Study 11093454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia Impact Questionnaire (FIQ)
Number of subjects: 0
Study 11093454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity ratings
Number of subjects: 0
Study 11093454 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of tender points
Number of subjects: 0
Study 11093454 — intervention group
Group type: EXPERIMENTAL
Intervention: Total tender point pain intensity score
Number of subjects: 0
Study 11093454 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall responsiveness of measures
Number of subjects: 0
Study 8801694 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit treatment
Number of subjects: 1241
Study 1505614 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg tid for 6 days (young subjects)
Number of subjects: 24
Study 1505614 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg tid for 6 days (elderly subjects)
Number of subjects: 24
Study 1505614 — intervention group
Group type: COMPARATOR
Intervention: Compliance measurement (both groups)
Number of subjects: 24
Study 6377973 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 1)
Number of subjects: 150
Study 6377973 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (Group 2)
Number of subjects: 150
Study 6377973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine at bedtime and in the morning (Group 3)
Number of subjects: 150
Study 6377973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine at bedtime and metoclopramide in the morning (Group 4)
Number of subjects: 150
Study 6377973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and metoclopramide in the morning (Group 5)
Number of subjects: 150
Study 6377973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine at bedtime and metoclopramide and cimetidine in the morning (Group 6)
Number of subjects: 150
Study 29447832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with grandmothers involved
Number of subjects: 323
Study 29447832 — intervention group
Group type: COMPARATOR
Intervention: Control group without grandmothers
Number of subjects: 323
Study 29447832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with teenagers only
Number of subjects: 323
Study 29408567 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) group (HIITG)
Number of subjects: 16
Study 29408567 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 16
Study 29408567 — intervention group
Group type: EXPERIMENTAL
Intervention: HIITG
Number of subjects: 16
Study 1427426 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant alpha-IFN (Roferon-A)
Number of subjects: 322
Study 1427426 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (hydroxyurea)
Number of subjects: 322
Study 22289904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg body weight) 4 hours before cardiopulmonary bypass
Number of subjects: 20
Study 22289904 — intervention group
Group type: COMPARATOR
Intervention: Natrium chloride
Number of subjects: 20
Study 20398394 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy simulator with rhythmic movement
Number of subjects: 37
Study 20398394 — intervention group
Group type: COMPARATOR
Intervention: Hippotherapy simulator without rhythmic movement
Number of subjects: 37
Study 18547839 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-eruption exposure
Number of subjects: 32
Study 18547839 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-eruption exposure
Number of subjects: 32
Study 15929755 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication group (received standard antibiotic therapy for H. pylori)
Number of subjects: 36
Study 15929755 — intervention group
Group type: COMPARATOR
Intervention: Non-eradication group (no treatment for H. pylori)
Number of subjects: 36
Study 15929755 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication group
Number of subjects: 36
Study 15929755 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (those who achieved complete or partial response)
Number of subjects: 36
Study 12628815 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose (3.3 microg) of TBE vaccine
Number of subjects: 30
Study 12628815 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated or vaccinated with basic immunisation and regular boosters)
Number of subjects: 30
Study 10656156 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment based on psychosomatic and physio-therapeutical principles, cognitive and operant behavioral therapy, 2.5 hours per week for 10 weeks.
Number of subjects: 53
Study 10656156 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment
Number of subjects: 53
Study 8689162 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 10
Study 8689162 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 10
Study 1794298 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodropropizine (60 mg active drug, oral drops, 12 h and 1 h before bronchoscopy)
Number of subjects: 16
Study 1794298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1794298 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodropropizine
Number of subjects: 16
Study 6610161 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 32
Study 6610161 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg)
Number of subjects: 32
Study 6610161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31471244 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide
Number of subjects: 12
Study 31471244 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin
Number of subjects: 12
Study 31471244 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination topical benzoyl peroxide and clindamycin
Number of subjects: 12
Study 31471244 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 12
Study 29102362 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 1200
Study 29102362 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1200
Study 28283134 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Chest Camp (SCC)
Number of subjects: 318
Study 28283134 — intervention group
Group type: COMPARATOR
Intervention: Infotainment Chest Camp (ICC)
Number of subjects: 318
Study 24845578 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hr interim test
Number of subjects: 106
Study 24845578 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hr interim test
Number of subjects: 106
Study 24845578 — intervention group
Group type: COMPARATOR
Intervention: No interim retrieval experience
Number of subjects: 106
Study 22481427 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine containing 3.75 μg A/H1N1 antigen
Number of subjects: 654
Study 22481427 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine containing 7.5 μg A/H1N1 antigen
Number of subjects: 654
Study 22481427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadjuvanted vaccine containing 15 μg A/H1N1 antigen
Number of subjects: 654
Study 22481427 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted formulations
Number of subjects: 654
Study 22481427 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 654
Study 20451184 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF‐9 c.G546A polymorphism
Number of subjects: 106
Study 20451184 — intervention group
Group type: COMPARATOR
Intervention: GDF‐9 c.G169A polymorphism
Number of subjects: 106
Study 20451184 — intervention group
Group type: COMPARATOR
Intervention: GDF‐9 c.C447T polymorphism
Number of subjects: 106
Study 17666715 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Infusion of 0.025 to 0.1 microg x kg(‐1) x min(‐1) with a PCA bolus of 0.25 microg x kg(‐1)
Number of subjects: 20
Study 17666715 — intervention group
Group type: COMPARATOR
Intervention: Group B: Infusion of 0.025 microg x kg(‐1) x min(‐1) with a PCA bolus increased from 0.25 to 1 microg x kg(‐1)
Number of subjects: 20
Study 17666715 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 18407883 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0
Study 18407883 — intervention group
Group type: COMPARATOR
Intervention: Diversified Placement Approach (DPA)
Number of subjects: 0
Study 18407883 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 0
Study 18407883 — intervention group
Group type: COMPARATOR
Intervention: DPA
Number of subjects: 0
Study 15469647 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (6.5 x 10(9) Lactobacillus casei Shirota cells twice daily)
Number of subjects: 19
Study 15469647 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (lactulose 10 g twice daily)
Number of subjects: 19
Study 15469647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11216978 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/day
Number of subjects: 50
Study 11216978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9284505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (4 mg)
Number of subjects: 7
Study 9284505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8451502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (Berotec)
Number of subjects: 12
Study 8451502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (Atrovent)
Number of subjects: 12
Study 8451502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3511127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn-like agent administered via a Nebulizer Chronolog, used four times a day for 12 weeks
Number of subjects: 19
Study 3511127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn-like agent
Number of subjects: 19
Study 11575289 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized reminders
Number of subjects: 6371
Study 11575289 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 6371
Study 31310464 — intervention group
Group type: EXPERIMENTAL
Intervention: HTK cardioplegic solution (Custodiol®)
Number of subjects: 50
Study 31310464 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hypothermic blood solution
Number of subjects: 50
Study 28927731 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated contact lenses
Number of subjects: 19
Study 28927731 — intervention group
Group type: COMPARATOR
Intervention: Uncoated contact lenses
Number of subjects: 19
Study 28051838 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS‐XR (mixed amphetamine salts) 60 mg and 80 mg combined
Number of subjects: 57
Study 28051838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 24613817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care with redeemed antihypertensive treatment
Number of subjects: 1533
Study 24613817 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detection and early treatment onset
Number of subjects: 1533
Study 24613817 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in cardiovascular risk factors (HbA1c, cholesterol, blood pressure, BMI)
Number of subjects: 1533
Study 24613817 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting treatment targets for HbA1c, cholesterol, and blood pressure
Number of subjects: 1533
Study 22713093 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 255
Study 22713093 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education
Number of subjects: 255
Study 22713093 — intervention group
Group type: COMPARATOR
Intervention: Brief Advice
Number of subjects: 255
Study 19801386 — intervention group
Group type: EXPERIMENTAL
Intervention: PECO with hypercapnia
Number of subjects: 11
Study 19801386 — intervention group
Group type: EXPERIMENTAL
Intervention: PECO while breathing room air
Number of subjects: 11
Study 19801386 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest with hypercapnia
Number of subjects: 11
Study 19801386 — intervention group
Group type: COMPARATOR
Intervention: Rest while breathing room air
Number of subjects: 11
Study 18040531 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions listed in the abstract
Number of subjects: 0
Study 16190797 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 536
Study 16190797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study 12079440 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment (statins and fibrates)
Number of subjects: 2856
Study 12079440 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of all prior lipid-lowering medications
Number of subjects: 2856
Study 12079440 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 2856
Study 10090490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 200 microg per vaginum q 12 h
Number of subjects: 30
Study 10090490 — intervention group
Group type: COMPARATOR
Intervention: Concentrated oxytocin plus low-dose vaginal prostaglandin E2 (10 mg q 6 h)
Number of subjects: 30
Study 7788255 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride (TCl) 20 mg twice daily
Number of subjects: 95
Study 7788255 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin (Oxy) 5 mg three times daily
Number of subjects: 95
Study 2138953 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disodium cromoglycate (DSCG)
Number of subjects: 24
Study 2138953 — intervention group
Group type: COMPARATOR
Intervention: Low-nickel diet
Number of subjects: 24